Tags

Type your tag names separated by a space and hit enter

Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Int Rev Neurobiol. 2010; 95:49-71.IR

Abstract

Long-term daily repeated intake of traditional levodopa (L-dopa)/dopa decarboxylase inhibitor (DDI) formulations increases the homocysteine synthesis in plasma of Parkinson's disease patients with unforeseen consequences, like an augmented vulnerability for onset of concomitant non-motor symptoms. Homocysteine decrease may therefore be a future therapeutic challenge, which may be achieved by supplementation with certain vitamins or by combination of a catechol-O-methyltransferase (COMT) inhibitor with L-dopa/DDI administration. Monitoring of plasma homocysteine concentration may also serve as biomarker for the detoxification potential of endogenous, exogenous, and environmental toxins. These substrates may also accumulate in the nervous system, since homocysteine formation is associated with O-methylation which has a broad detoxification potential.

Authors+Show Affiliations

Department of Neurology, St. Joseph Hospital, Berlin, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21095459

Citation

Müller, Thomas. "Catechol-O-methyltransferase Enzyme: Cofactor S-adenosyl-L-methionine and Related Mechanisms." International Review of Neurobiology, vol. 95, 2010, pp. 49-71.
Müller T. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. Int Rev Neurobiol. 2010;95:49-71.
Müller, T. (2010). Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. International Review of Neurobiology, 95, 49-71. https://doi.org/10.1016/B978-0-12-381326-8.00004-1
Müller T. Catechol-O-methyltransferase Enzyme: Cofactor S-adenosyl-L-methionine and Related Mechanisms. Int Rev Neurobiol. 2010;95:49-71. PubMed PMID: 21095459.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. A1 - Müller,Thomas, PY - 2010/11/25/entrez PY - 2010/11/26/pubmed PY - 2011/3/8/medline SP - 49 EP - 71 JF - International review of neurobiology JO - Int Rev Neurobiol VL - 95 N2 - Long-term daily repeated intake of traditional levodopa (L-dopa)/dopa decarboxylase inhibitor (DDI) formulations increases the homocysteine synthesis in plasma of Parkinson's disease patients with unforeseen consequences, like an augmented vulnerability for onset of concomitant non-motor symptoms. Homocysteine decrease may therefore be a future therapeutic challenge, which may be achieved by supplementation with certain vitamins or by combination of a catechol-O-methyltransferase (COMT) inhibitor with L-dopa/DDI administration. Monitoring of plasma homocysteine concentration may also serve as biomarker for the detoxification potential of endogenous, exogenous, and environmental toxins. These substrates may also accumulate in the nervous system, since homocysteine formation is associated with O-methylation which has a broad detoxification potential. SN - 2162-5514 UR - https://www.unboundmedicine.com/medline/citation/21095459/Catechol_O_methyltransferase_enzyme:_cofactor_S_adenosyl_L_methionine_and_related_mechanisms_ L2 - https://linkinghub.elsevier.com/retrieve/pii/B978-0-12-381326-8.00004-1 DB - PRIME DP - Unbound Medicine ER -